Breast Cancer

Genetic changes to BRCA1 predicts higher risk of breast and ovarian cancers.

Treating modifiable risk factors could enhance breast cancer prevention.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Breast cancer cells found to hide in bone marrow before resurging.

Researchers were able to better predict the risk of developing breast cancer.

The protein GlyRS helps modify proteins that cause cancer growth.

Doxorubicin, all-trans retinoic acid, and entinostat significantly reduced triple-negative breast cancer tumors in mice.

Postmenopausal patients with invasive ductal carcinomas had high levels of saturated fats.

Researchers find indicators of poor chemotherapy response.

Women older than age 65 face higher risk for several comorbidities from breast cancer treatment.

Uncialamycin may effectively treat various cancer types, including gastric, lung, and ovarian cancers.

The drug eCF506 can selectively block the Src tyrosine kinase and stop the growth of breast cancer cells.

Rapalink able to inhibit growth in drug-resistant tumors across different cancer types.

Higher doses of radiation found as effective as lower dose radiation for breast cancer treatment.

Study finds a large proportion of breast cancer patients are receiving enough follow-up heart scans.

Researchers assess the monetary value for improved health status.

RANK-inhibitor denosumab was able to stop cell growth and reduce cancer development in breast cancer samples with mutated-BRCA1.

Efficacy of aromatase inhibitors reduced among breast cancer patients who smoke.

Reading mammograms for longer periods of time did not reduce cancer detection, but increased overall performance.

Promising new technique revealed for stopping tumor cell migration.

Several factors can affect whether women diagnosed with breast cancer begin chemotherapy.

Nanostructured lipid carriers containing melatonin adjuvant to tamoxifen killed more breast cancer cells than tamoxifen alone.

A combination of doxorubicin, all-trans retinoic acid, and entinostat shrank triple-negative breast cancer tumors by 90%.

Discovery may determine the best therapeutic option for breast cancer patients.